Cortical morphometry and neural dysfunction in Huntington's disease: a review.
Huntington's disease
cortical morphometry
network spread hypothesis
neuroimaging
neuronal dysfunction
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
27
07
2020
revised:
22
09
2020
accepted:
12
11
2020
pubmed:
20
11
2020
medline:
13
8
2021
entrez:
19
11
2020
Statut:
ppublish
Résumé
Numerous neuroimaging techniques have been used to identify biomarkers of disease progression in Huntington's disease (HD). To date, the earliest and most sensitive of these is caudate volume; however, it is becoming increasingly evident that numerous changes to cortical structures, and their interconnected networks, occur throughout the course of the disease. The mechanisms by which atrophy spreads from the caudate to these cortical regions remains unknown. In this review, the neuroimaging literature specific to T1-weighted and diffusion-weighted magnetic resonance imaging is summarized and new strategies for the investigation of cortical morphometry and the network spread of degeneration in HD are proposed. This new avenue of research may enable further characterization of disease pathology and could add to a suite of biomarker/s of disease progression for patient stratification that will help guide future clinical trials.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1406-1419Informations de copyright
© 2020 European Academy of Neurology.
Références
De Souza RAG, Leavitt BR. Neurobiology of Huntington’s disease. In HHP Nguyen, MA Cenci, Behavioral Neurobiology of Huntington’s Disease and Parkinson’s Disease. Berlin, Heidelberg: Springer; 2014:81-100.
MacDonald ME, Ambrose CM, Duyao MP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72(6):971-983.
Bates G, Tabrizi S, Jones L. Huntington’s Disease. Oxford, UK: Oxford University Press; 2014.
Labbadia J, Morimoto RI. Huntington’s disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci. 2013;38(8):378-385.
Myers RH. Huntington’s disease genetics. NeuroRx. 2004;1(2):255-262.
Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204.
Walker FO. Huntington’s disease. Lancet. 2007;369(9557):218-228.
Kieburtz K, Penney JB, Corno P, et al. Unified Huntington’s disease rating scale: reliability and consistency. Neurology. 2001;11(2):136-142.
Margolis RL, Ross CA. Diagnosis of Huntington disease. Clin Chem. 2003;49(10):1726-1732.
Tabrizi SJ, Reilmann R, Roos RAC, et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012;11(1):42-53.
Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10(1):31-42.
Georgiou-Karistianis N, Hannan AJ, Egan GF, et al. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington’s disease. Brain Res Rev. 2008;58(1):209-225.
Georgiou-Karistianis N, Scahill R, Tabrizi SJ, Squitieri F, Aylward E. Structural MRI in Huntington’s disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev. 2013;37(3):480-490.
Dema MG, Borrelli C, Migliore S, Fusilli C. F75 A huntington’s disease (HD) database at lirh foundation (LIRH-rome site): enroll-hd study as a starting point. J Neurol Neurosurg Psychiatry. 2018;89(Suppl 1). https://doi.org/10.1136/jnnp-2018-EHDN.173
Wijeratne PA, Young AL, Oxtoby NP, et al. An image-based model of brain volume biomarker changes in Huntington’s disease. Ann Clin Transl Neurol. 2018;5(5):570-582.
Domínguez JF, Stout JC, Poudel G, et al. Multimodal imaging biomarkers in premanifest and early Huntington’s disease: 30-month IMAGE-HD data. Br J Psychiatry. 2016;208(6):571-578.
Georgiou-Karistianis N, Poudel GR, Langmaid R, et al. Functional and connectivity changes during working memory in Huntington’s disease: 18 month longitudinal data from the IMAGE-HD study. Brain Cogn. 2013;83(1):80-91.
Georgiou-Karistianis N, Sritharan A, Asadi H, Johnston L, Churchyard A, Egan G. Diffusion tensor imaging in Huntington’s disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav. 2011;5(3):171-180.
McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur J Neurol. 2018;25(1):24-34. https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.13413
Poudel GR, Stout JC, Churchyard A, Chua P, Egan GF, Georgiou-Karistianis N. Longitudinal change in white matter microstructure in Huntington’s disease: the IMAGE-HD study. Neurobiol Dis. 2015;74:406-412.
Scahill RI, Andre R, Tabrizi SJ, Aylward EH. Structural imaging in premanifest and manifest Huntington disease. Handbook of Clinical Neurology. Vol 144 Amsterdam: Elsevier. 2017;247-261.
Georgiou-Karistianis N, Gray MA, Dymowski AR, et al. Automated differentiation of pre-diagnosis Huntington’s disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: the IMAGE-HD study. Neurobiol Dis. 2013;51:82-92.
Paulsen JS, Long JD, Johnson HJ, et al. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci. 2014;6:78.
Colpo GD, Rocha NP, Stimming EF, Teixeira AL. Immunomodulatory strategies for Huntington’s disease treatment. CNS Neurol Disord Targets (formerly Curr Drug Targets-CNS Neurol Disord. 2017;16(8):936-944.
Connor B. Concise review: the use of stem cells for understanding and treating Huntington’s disease. Stem Cells. 2018;36(2):146-160.
Travessa AM, Rodrigues FB, Mestre TA, Ferreira JJ. Fifteen years of clinical trials in Huntington’s disease: a very low clinical drug development success rate. J Huntingtons Dis. 2017;6(2):157-163.
Rodrigues FB, Wild EJ. Huntington’s disease clinical trials corner: February 2018. J Huntingtons Dis. 2018;7(1):89.
Tabrizi SJ, Leavitt B, Landwehrmeyer B, et al. J01 Effects of IONIS-HTTRX (RG6042) in patients with early huntington’s disease, results of the first htt-lowering drug trial. Neurol Neurosurg Psychiatry. 2018;89(Suppl 1). https://doi.org/10.1136/jnnp-2018-EHDN.261
Schobel S, Palermo G, Trundell D, et al. A global development program testing RG6042, an antisense oligonucleotide, for the treatment of early manifest Huntington’s disease. J Neurol Neurosurg Psychiatry. 2018;89:A98. BMJ Publishing Group British Med Assoc House, Tavistock Square, London, WC1H.
Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington’s disease. Neuron. 2019;101(5):801-819.
Niccolini F, Politis M. Neuroimaging in Huntington’s disease. World J Radiol. 2014;6(6):301.
Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Huntington’s disease in asymptomatic at-risk persons. Neurology. 1994;44(5):823.
Fischl B. FreeSurfer. Neuroimage. 2012;62(2):774-781.
Perlaki G, Horvath R, Nagy SA, et al. Comparison of accuracy between FSL’s FIRST and Freesurfer for caudate nucleus and putamen segmentation. Sci Rep. 2017;7(1):2418.
Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage. 2004;23:S208-S219.
Ashburner J, Friston KJ. Voxel-based morphometry-the methods. NeuroImage. 2000;11(6):805-821.
Johnson EB, Gregory S, Johnson HJ, et al. Recommendations for the use of automated gray matter segmentation tools: evidence from Huntington’s disease. Front Neurol. 2017;8:519.
Paulsen LDR, Stout JC, et al. Detection of Huntington’s disease decades before diagnosis: the PREDICT-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874-880.
Paulsen JS, Long JD, Ross CA, et al. Prediction of manifest Huntington’s disease with clinical and imaging measures: a prospective observational study. Lancet Neurol. 2014;13(12):1193-1201.
Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791-801.
Domínguez DJF, Egan GF, Gray MA, et al. Multi-modal neuroimaging in premanifest and early Huntington’s disease: 18 month longitudinal data from the IMAGE-HD study. PLoS One. 2013;8(9):e74131. https://doi.org/10.1371/journal.pone.0074131
Campodonico JR, Aylward E, Codori A-M, et al. When does Huntington’s disease begin? J Int Neuropsychol Soc. 1998;4(5):467-473.
Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington’s disease. Brain. 1999;122(9):1667-1678.
Paulsen JS, Magnotta VA, Mikos AE, et al. Brain structure in preclinical Huntington’s disease. Biol Psychiatry. 2006;59(1):57-63.
Douaud G, Gaura V, Ribeiro M-J, et al. Distribution of grey matter atrophy in Huntington’s disease patients: a combined ROI-based and voxel-based morphometric study. NeuroImage. 2006;32(4):1562-1575.
Nopoulos PC. Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neurosci. 2016;18(1):91.
Paulsen JS, Nopoulos PC, Aylward E, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010;82(3-4):201-207.
Vonsattel J-P, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol. 1985;44(6):559-577.
Mühlau M, Gaser C, Wohlschläger AM, et al. Striatal gray matter loss in Huntington’s disease is leftward biased. Mov Disord. 2007;22(8):1169-1173.
Aylward EH, Codori A-M, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol. 1996;53(12):1293-1296.
Aylward EH, Codori AM, Rosenblatt A, et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease. Mov Disord. 2000;15(3):552-560.
Thieben MJ, Duggins AJ, Good CD, et al. The distribution of structural neuropathology in pre-clinical Huntington’s disease. Brain. 2002;125(8):1815-1828.
Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the PREDICT-HD study. Arch Neurol. 2006;63(6):883-890.
Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637-649.
Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington’s disease. Neurology. 1997;48(2):394-399.
Coppen EM, Jacobs M, van den Berg-Huysmans AA, van der Grond J, Roos RAC. Grey matter volume loss is associated with specific clinical motor signs in Huntington’s disease. Parkinsonism Relat Disord. 2018;46:56-61.
Jurgens CK, Van de Wiel L, Van Es ACGM, et al. Basal ganglia volume and clinical correlates in “preclinical” Huntington’s disease. J Neurol. 2008;255(11):1785.
Kipps CM, Duggins AJ, Mahant N, Gomes L, Ashburner J, McCusker EA. Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study. J Neurol Neurosurg Psychiatry. 2005;76(5):650-655.
Rosas HD, Koroshetz WJ, Chen YI, et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 2003;60(10):1615-1620.
Ahveninen LM, Stout JC, Georgiou-Karistianis N, Lorenzetti V, Glikmann-Johnston Y. Reduced amygdala volumes are related to motor and cognitive signs in Huntington’s disease: the IMAGE-HD study. NeuroImage Clin. 2018;18:881-887.
Bäckman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington’s disease are predicted by dopaminergic PET markers and brain volumes. Brain J Neurol. 1997;120(12):2207-2217.
Jernigan TL, Salmon DP, Butters N, Hesselink JR. Cerebral structure on MRI, Part II: Specific changes in Alzheimer’s and Huntington’s diseases. Biol Psychiatry. 1991;29(1):68-81.
Starkstein SE, Brandt J, Bylsma F, Peyser C, Folstein M, Folstein SE. Neuropsychological correlates of brain atrophy in Huntington’s disease: a magnetic resonance imaging study. Neuroradiology. 1992;34(6):487-489.
Gómez-Ansón B, Alegret M, Munoz E, et al. Prefrontal cortex volume reduction on MRI in preclinical Huntington’s disease relates to visuomotor performance and CAG number. Parkinsonism Relat Disord. 2009;15(3):213-219.
Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J. Executive dysfunction in early stages of Huntington’s disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci. 2005;239(1):11-19.
Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2011;82(4):405-410.
Aylward EH, Anderson NB, Bylsma FW, et al. Frontal lobe volume in patients with Huntington’s disease. Neurology. 1998;50(1):252-258.
Labuschagne I, Cassidy AM, Scahill RI, et al. Visuospatial processing deficits linked to posterior brain regions in premanifest and early stage Huntington’s disease. J Int Neuropsychol Soc. 2016;22(6):595-608.
Poudel GR, Stout JC, Salmon L, et al. White matter connectivity reflects clinical and cognitive status in Huntington’s disease. Neurobiol Dis. 2014;65:180-187.
Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry. 2008;79(2):130-135.
van der Plas E, Langbehn DR, Conrad AL, et al. Abnormal brain development in child and adolescent carriers of mutant huntingtin. Neurology. 2019;93(10):e1021-e1030.
Lee JK, Mathews K, Schlaggar B, et al. Measures of growth in children at risk for Huntington disease. Neurology. 2012;79(7):668-674. https://doi.org/10.1212/WNL.0b013e3182648b65
Tereshchenko A, Magnotta V, Epping E, et al. Brain structure in juvenile-onset Huntington disease. Neurology. 2019;92(17):e1939-e1947.
Tereshchenko AV, Schultz JL, Bruss JE, Magnotta VA, Epping EA, Nopoulos PC. Abnormal development of cerebellar-striatal circuitry in Huntington disease. Neurology. 2020;94(18):e1908-e1915.
Mehler MF, Gokhan S. Mechanisms underlying neural cell death in neurodegenerative diseases: alterations of a developmentally-mediated cellular rheostat. Trends Neurosci. 2000;23(12):599-605.
Amaral DG, Li D, Libero L, et al. In pursuit of neurophenotypes: the consequences of having autism and a big brain. Autism Res. 2017;10(5):711-722.
Scahill RI, Zeun P, Osborne-Crowley K, et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 2020;19(6):502-512.
Politis M. Imaging in Movement Disorders: Imaging in Atypical Parkinsonism and Familial Movement Disorders, vol. 142. Cambridge, MA: Academic Press; 2018.
Harris GJ, Pearlson GD, Peyser CE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington’s disease. Ann Neurol. 1992;31(1):69-75.
Aylward EH, Harrington DL, Mills JA, et al. Regional atrophy associated with cognitive and motor function in prodromal Huntington disease. J Huntingtons Dis. 2013;2(4):477-489.
van den Bogaard SJA, Dumas EM, Acharya TP, et al. Early atrophy of pallidum and accumbens nucleus in Huntington’s disease. J Neurol. 2011;258(3):412-420.
Winder JY, Achterberg WP, Gardiner SL, Roos RAC. Longitudinal assessment of the Unified Huntington’s Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington’s disease. Eur J Neurol. 2019;26(5):780-785.
Arney K. Improved metrics for Huntington’s disease trials. Nature. 2018;557(7707):S46.
Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Prim. 2015;1:15005.
Winder JY, Roos RAC, Burgunder J, Marinus J, Reilmann R. Interrater reliability of the Unified Huntington’s Disease Rating Scale-total motor score certification. Mov Disord Clin Pract. 2018;5(3):290-295.
Schobel SA, Palermo G, Auinger P, et al. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017;89(24):2495-2502. https://doi.org/10.1212/WNL.0000000000004743
Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A. 2002;99(4):1876-1881. https://doi.org/10.1073/pnas.261709098
van den Bogaard SJA, Dumas EM, Ferrarini L, et al. Shape analysis of subcortical nuclei in Huntington’s disease, global versus local atrophy-results from the TRACK-HD study. J Neurol Sci. 2011;307(1):60-68.
Reiner A, Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci. 1988;85(15):5733-5737.
Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology. 2004;63(1):66-72.
Brand J, Bylsma FW, Aylward EH, Rothlind J, Gow CA. Impaired source memory in Huntington’s disease and its relation to basal ganglia atrophy. J Clin Exp Neuropsychol. 1995;17(6):868-877.
Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol. 1993;50(8):873-880.
Leh SE, Ptito A, Chakravarty MM, Strafella AP. Fronto-striatal connections in the human brain: a probabilistic diffusion tractography study. Neurosci Lett. 2007;419(2):113-118.
Minkova L, Gregory S, Scahill RI, et al. Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington’s disease. NeuroImage Clin. 2018;17:312-324.
Wu D, Faria AV, Younes L, et al. Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington’s disease. Hum Brain Mapp. 2017;38(10):5035-5050.
Blanken LME, Mous SE, Ghassabian A, et al. Cortical morphology in 6- to 10-year-old children with autistic traits: a population-based neuroimaging study. Am J Psychiatry. 2015;172(5):479-486.
Hardan AY, Jou RJ, Keshavan MS, Varma R, Minshew NJ. Increased frontal cortical folding in autism: a preliminary MRI study. Psychiatry Res Neuroimaging. 2004;131(3):263-268.
Im K, Lee J-M, Seo SW, Kim SHI, Kim SHI, Na DL. Sulcal morphology changes and their relationship with cortical thickness and gyral white matter volume in mild cognitive impairment and Alzheimer’s disease. NeuroImage. 2008;43(1):103-113.
Jubault T, Gagnon J-F, Karama S, et al. Patterns of cortical thickness and surface area in early Parkinson’s disease. NeuroImage. 2011;55(2):462-467.
Pereira JB, Ibarretxe-Bilbao N, Marti M, et al. Assessment of cortical degeneration in patients with Parkinson’s disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp. 2012;33(11):2521-2534.
Ramírez-Ruiz B, Martí MJ, Tolosa E, et al. Longitudinal evaluation of cerebral morphological changes in Parkinson’s disease with and without dementia. J Neurol. 2005;252(11):1345-1352.
Nopoulos MVA, Mikos A, et al. Morphology of the cerebral cortex in preclinical Huntington’s disease. Am J Psychiatry. 2007;164(9):1428-1434.
Shishegar R, Manton JH, Walker DW, Britto JM, Johnston LA. Quantifying gyrification using Laplace Beltrami eigenfunction level-sets. InIEEE 12th International Symposium on Biomedical Imaging (ISBI). IEEE. 2015:1272-1275.
Fischl B, Rajendran N, Busa E, et al. Cortical folding patterns and predicting cytoarchitecture. Cereb Cortex. 2007;18(8):1973-1980.
Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington’s disease. Neurosci Lett. 1991;133(2):257-261.
Di Martino A, Scheres A, Margulies DS, et al. Functional connectivity of human striatum: a resting state fMRI study. Cereb Cortex. 2008;18(12):2735-2747.
Draganski B, Kherif F, Klöppel S, et al. Evidence for segregated and integrative connectivity patterns in the human basal ganglia. J Neurosci. 2008;28(28):7143-7152.
Chen H, Dou Q, Yu L, Qin J, Heng P-A. VoxResNet: deep voxelwise residual networks for brain segmentation from 3D MR images. NeuroImage. 2018;170:446-455.
Shishegar R, Joshi AA, Tolcos M, Walker DW, Johnston LA.Automatic segmentation of fetal brain using diffusion-weighted imaging cues. In: Proceedings-International Symposium on Biomedical Imaging (ISBI). IEEE; 2017:804-807. 10.1109/ISBI.2017.7950640
Lyu I, Kim SH, Girault JB, Gilmore JH, Styner MA. A cortical shape-adaptive approach to local gyrification index. Med Image Anal. 2018;48:244-258.
Plocharski M, Østergaard LR, Initiative ADN. Extraction of sulcal medial surface and classification of Alzheimer’s disease using sulcal features. Comput Methods Programs Biomed. 2016;133:35-44.
Rosas HD, Liu AK, Hersch S, et al. Regional and progressive thinning of the cortical ribbon in Huntington’s disease. Neurology. 2002;58(5):695-701.
Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology. 2005;65(5):745-747.
Nopoulos PC, Aylward EH, Ross CA, et al. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis. 2010;40(3):544-554.
Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain. 2008;131(4):1057-1068.
Kubera KM, Schmitgen MM, Hirjak D, Wolf RC, Orth M. Cortical neurodevelopment in pre-manifest Huntington’s disease. NeuroImage Clin. 2019;23:101913.
Shishegar R, Rajapakse S, Georgiou-Karistianis NAltered cortical morphometry in pre-manifest Huntington’s disease: cross-sectional data from the IMAGE-HD study. In 41st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE. 2019;2019:2844-2847.
Mascalchi M, Lolli F, Della NR, et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. Radiology. 2004;232(3):867-873.
Seppi K, Schocke MFH, Mair KJ, et al. Diffusion-weighted imaging in Huntington’s disease. Mov Disord. 2006;21(7):1043-1047.
Rosas HD, Goodman J, Chen YI, et al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology. 2001;57(6):1025-1028.
Vonsattel JPG, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369.
Heinsen H, Rüb U, Bauer M, et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington’s disease. Acta Neuropathol. 1999;97(6):613-622.
Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson. 2011;213(2):560-570.
Concha L, Gross DW, Wheatley BM, Beaulieu C. Diffusion tensor imaging of time-dependent axonal and myelin degradation after corpus callosotomy in epilepsy patients. NeuroImage. 2006;32(3):1090-1099.
Jones DK, Knösche TR, Turner R. White matter integrity, fiber count, and other fallacies: the do’s and don’ts of diffusion MRI. NeuroImage. 2013;73:239-254.
Soares J, Marques P, Alves V, Sousa N. A hitchhiker’s guide to diffusion tensor imaging. Front Neurosci. 2013;7:31.
Klöppel S, Draganski B, Golding CV, et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington’s disease. Brain. 2007;131(1):196-204.
Rosas HD, Lee SY, Bender AC, et al. Altered white matter microstructure in the corpus callosum in Huntington’s disease: implications for cortical “disconnection”. NeuroImage. 2010;49(4):2995-3004.
Rosas HD, Tuch DS, Hevelone ND, et al. Diffusion tensor imaging in presymptomatic and early Huntington’s disease: selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006;21(9):1317-1325.
Reading SAJ, Yassa MA, Bakker A, et al. Regional white matter change in pre-symptomatic Huntington’s disease: a diffusion tensor imaging study. Psychiatry Res Neuroimaging. 2005;140(1):55-62. https://doi.org/10.1016/j.pscychresns.2005.05.011
McColgan P, Seunarine KK, Gregory S, et al. Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington’s disease. JCI insight. 2017;2(8):e92641.
Poudel GR, Stout JC, Gray MA, et al. Functional changes during working memory in Huntington’s disease: 30-month longitudinal data from the IMAGE-HD study. Brain Struct Funct. 2015;220(1):501-512.
Bohanna I, Georgiou-Karistianis N, Egan GF. Connectivity-based segmentation of the striatum in Huntington’s disease: vulnerability of motor pathways. Neurobiol Dis. 2011;42(3):475-481. https://doi.org/10.1016/j.nbd.2011.02.010
Marrakchi-Kacem L, Delmaire C, Guevara P, et al. Mapping cortico-striatal connectivity onto the cortical surface: a new tractography-based approach to study Huntington disease. PLoS One. 2013;8(2):e53135.
Phillips O, Sanchez-Castaneda C, Elifani F, et al. Tractography of the corpus callosum in Huntington’s disease. PLoS One. 2013;8(9):e73280.
Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73(6):1216-1227.
Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer’s disease. J Neurosci. 2009;29(6):1860-1873.
Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem. 2009;284(6):3546-3551.
Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70(4):532-540.
Ridley RM, Baker HF, Windle CP, Cummings RM. Very long term studies of the seeding of β-amyloidosis in primates. J Neural Transm. 2006;113(9):1243.
Walker LC, LeVine H III, Mattson MP, Jucker M. Inducible proteopathies. Trends Neurosci. 2006;29(8):438-443.
Babcock DT, Ganetzky B. Transcellular spreading of huntingtin aggregates in the Drosophila brain. Proc Natl Acad Sci. 2015;112(39):E5427-E5433. https://doi.org/10.1073/pnas.1516217112
Poudel GR, Harding IH, Egan GF, Georgiou-Karistianis N. Network spread determines severity of degeneration and disconnection in Huntington’s disease. Hum Brain Mapp. 2019;40(14):4192-4201. https://doi.org/10.1002/hbm.24695
Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709-7717.
Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62(1):42-52. https://doi.org/10.1016/j.neuron.2009.03.024
Yau Y, Zeighami Y, Baker TE, et al. Network connectivity determines cortical thinning in early Parkinson’s disease progression. Nat Commun. 2018;9(1):12.
Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron. 2012;73(6):1204-1215.
Torok J, Maia PD, Powell F, Pandya S, Raj A. A method for inferring regional origins of neurodegeneration. Brain. 2018;141(3):863-876.
Poudel GR, Domıngue JFD, Verhelst H, et al. Network diffusion modelling predicts neurodegeneration in traumatic brain injury. Ann Clin Transl Neurol Press. 2020;7(3):270-279.
Carter CS, Lesh TA, Barch DM. Thresholds, power, and sample sizes in clinical neuroimaging. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1(2):99-100.
Button KS, Ioannidis JPA, Mokrysz C, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14(5):365-376.
Poldrack RA, Baker CI, Durnez J, et al. Scanning the horizon: towards transparent and reproducible neuroimaging research. Nat Rev Neurosci. 2017;18(2):115.
Soloveva MV, Jamadar SD, Poudel G, Georgiou-Karistianis N. A critical review of brain and cognitive reserve in Huntington’s disease. Neurosci Biobehav Rev. 2018;88:155-169.
Wijeratne PA, Johnson EB, Eshaghi A, et al. Robust markers and sample sizes for multicenter trials of Huntington disease. Ann Neurol. 2020;87(5):751-762.
Bearden CE, Thompson PM. Emerging global initiatives in neurogenetics: the enhancing neuroimaging genetics through meta-analysis (ENIGMA) consortium. Neuron. 2017;94(2):232-236.
Miller KL, Alfaro-Almagro F, Bangerter NK, et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. Nat Neurosci. 2016;19(11):1523-1536.
Gray MA, Egan GF, Ando A, et al. Prefrontal activity in Huntington’s disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study. Exp Neurol. 2013;239:218-228.
Beglinger LJ, Nopoulos PC, Jorge RE, et al. White matter volume and cognitive dysfunction in early Huntington's disease. Cogn. Affect. Behav. Neurosci. 2005;18 2:102-107.